Half-year report · HY
177A.TEDINET S100X2IH
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥258m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥272m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥274m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥916m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥518m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥220m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.53 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥157.57 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 65.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥283m |
| Cell Process Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥76m |
| Microbiological Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥36m |
| Tissue Culture Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥501m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥541m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash dividends paid fin cf | Prior1InterimDuration | -58310000 | JPY |
| Cash dividends paid fin cf | InterimDuration | -120457000 | JPY |
| Other net fin cf | Prior1InterimDuration | -6620000 | JPY |
| Other net fin cf | InterimDuration | -1000000 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 1485818000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | -219827000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | 42575000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | -25223000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 1579843000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -561451000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1726936000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2949267000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 3306780000 | JPY |
| Cash and cash equivalents | InterimInstant | 2387815000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | 12000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | -31000 | JPY |
| Payroll and allowances sga | Prior1InterimDuration | 169405000 | JPY |
| Payroll and allowances sga | InterimDuration | 172148000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 31856000 | JPY |
| Provision for bonuses sga | InterimDuration | 23579000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 1874000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 1060000 | JPY |
| Commission fee sga | Prior1InterimDuration | 118066000 | JPY |
| Commission fee sga | InterimDuration | 86729000 | JPY |
| Research and development expenses sga | Prior1InterimDuration | 85406000 | JPY |
| Research and development expenses sga | InterimDuration | 143364000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 1101203000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | 776768000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 629614000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 2507586000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 2507586000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 1101203000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | 776768000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 629614000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 2507586000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 2507586000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E38689-000TissueCultureBusinessReportableSegmentMember | 350330000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E38689-000MicrobiologicalBusinessReportableSegmentMember | 103735000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E38689-000CellProcessBusinessReportableSegmentMember | 190773000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 644840000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -265057000 | JPY |
| Operating income | Prior1InterimDuration | 379782000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |